MedTrace Logo

Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes

NCT02612012 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 475

Last updated 2015-11-23

No results posted yet for this study

Summary

This study is designed to evaluate the feasibility and safety of axillary radiotherapy for early stage breast cancer with limited positive sentinel lymph nodes.

Conditions

Interventions

RADIATION

axillary radiotherapy

Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xiaoli Yu, MD.PhD · Fudan University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2019-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612012 on ClinicalTrials.gov